TAKEDA PHARMACEUTICAL CO LTD current report, Q3 FY2021

Vollständiges Dokument

Takeda Pharmaceutical Co Ltd: Q1 FY2021 Financial Summary

Business Context and Reporting Period

This Form 6-K filing summarizes the consolidated financial results for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2021 (Q1 FY2021). The company operates globally with major therapeutic areas including Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience. The reporting period covers April 1, 2021, to June 30, 2021.

Key Financial Metrics

Metric Q1 FY2021 (JPY) Q1 FY2020 (JPY) Change (%)
Revenue 949,603 Million 801,850 Million +18.4%
Operating Profit 248,552 Million 167,285 Million +48.6%
Profit Before Tax 222,978 Million 130,291 Million +71.1%
Net Profit (Period) 200,421 Million 82,519 Million +142.9%
Net Profit (Attributable to Owners) 200,378 Million 82,511 Million +142.8%
Basic EPS 128.02 JPY 52.93 JPY +141.9%
Core Operating Profit 248.9 Billion 280.9 Billion -11.4%
Core EPS 113 JPY 122 JPY -7.4%

Balance Sheet (as of June 30, 2021):

  • Total Assets: 12,657,234 Million JPY (Decreased 255.1 Billion JPY from FY2020 year-end).
  • Total Equity: 5,300,159 Million JPY (Increased 123.0 Billion JPY from FY2020 year-end).
  • Equity Ratio: 41.9%.
  • Cash and Cash Equivalents: 654,920 Million JPY (Decreased 311.3 Billion JPY from FY2020 year-end).
  • Bonds and Loans: 4,405.9 Billion JPY (Decreased 229.5 Billion JPY due to repayments).

Cash Flow (Q1 FY2021):

  • Operating Cash Flow: +166.9 Billion JPY.
  • Investing Cash Flow: -70.4 Billion JPY.
  • Financing Cash Flow: -411.0 Billion JPY (Driven by debt repayments).

Material Changes vs. Prior Period

Revenue Growth Drivers: Reported revenue increased 18.4% year-over-year. This was significantly impacted by a one-time gain of 133.0 Billion JPY from the sale of a diabetes product portfolio in Japan to Teijin Pharma Limited in April 2021, which accounted for 16.6 percentage points of the growth. Excluding this sale and foreign exchange effects, underlying revenue growth was 3.8%.

Profitability: Operating profit surged 48.6% to 248.6 Billion JPY. This increase was driven by higher revenue, a decrease in income tax expenses (due to restructuring benefits), and a reduction in other operating expenses compared to the prior year. However, Core Operating Profit (excluding non-recurring items) decreased 11.4% to 248.9 Billion JPY, primarily due to increased R&D investment and foreign exchange headwinds.

Therapeutic Area Performance:

  • Gastroenterology (GI): Revenue up 12.6%, driven by strong sales of ENTYVIO (+23.9%) and TAKECAB (+20.1%).
  • Rare Diseases: Revenue flat (+0.3%). Rare Metabolic grew 10.9%, while Rare Hematology declined 5.9% due to competition.
  • Oncology: Revenue up 12.4%, led by VELCADE (+24.6%) and ADCETRIS (+14.2%).
  • Neuroscience: Revenue up 6.1%, driven by VYVANSE/ELVANSE (+20.0%).

Expense Trends: R&D expenses increased 14.7% to 122.5 Billion JPY due to investment in new molecular entities. SG&A expenses rose 8.6% largely due to the depreciation of the yen.

Guidance, Outlook, and Risks

Full Year FY2021 Forecast (Ending March 31, 2022): Management has not revised its original forecast.

  • Revenue: 3,370 Billion JPY (+5.4% YoY).
  • Operating Profit: 488 Billion JPY (-4.2% YoY).
  • Net Profit: 250 Billion JPY (-33.5% YoY).
  • Core Operating Profit: 930 Billion JPY (-3.9% YoY).
  • Free Cash Flow: 600-700 Billion JPY.

Management Guidance (Underlying Metrics):

  • Underlying Revenue Growth: Mid-single-digit growth.
  • Underlying Core Operating Profit Growth: Mid-single-digit growth.
  • Underlying Core Operating Profit Margin: ~30%.
  • Underlying Core EPS Growth: Mid-single-digit growth.

Risks and Contingencies:

  • COVID-19: While the pandemic did not materially impact Q1 results, management notes that future outbreaks or lockdowns could disrupt demand, supply chains, and clinical trials.
  • Competition: Takeda expects a 505(b)2 competitor for subcutaneous VELCADE to launch in the U.S. around mid-FY2021.
  • Divestitures: The forecast excludes impacts from potential further divestitures beyond those already disclosed.
  • Foreign Exchange: Fluctuations in currency rates remain a significant variable affecting reported results.

Investor Verification Checklist

  • One-Time Gains: Verify the impact of the 133.0 Billion JPY diabetes portfolio sale on Q1 revenue and the exclusion of this item in Core/Underlying metrics.
  • Core vs. Reported Profit: Note the divergence between reported profit growth (+142.9%) and Core Operating Profit decline (-11.4%) to understand the quality of earnings.
  • Debt Reduction: Confirm the repayment of 2.0 Billion USD in loans and the redemption of senior notes, reducing total debt significantly.
  • Dividend Policy: Verify the projected total annual dividend of 180.00 JPY per share for FY2021.
  • FX Sensitivity: Assess the impact of the weak yen on reported revenue growth versus underlying constant currency growth.